View the latest news and SEC filings
Scroll to
Ohtuvayre TM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Ohtuvayre through February 2025 Phase 2 programs in
LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in March 2025: TD Cowen 45 th Annual Health Care Conference Date: Monday,
LONDON and RALEIGH, N.C., Feb. 13, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth quarter and full year ended December 31, 2024 on Thursday, February 27, 2025 and host an investment
Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively More than 3,500 unique prescribers and over 16,000 prescriptions filled in 2024 across a broad COPD population Approximately 45% of Tier 1 HCPs prescribed Ohtuvayre
| Date | Form | Filing Group | ||
|---|---|---|---|---|
|
February 13, 2017 |
A statement of beneficial ownership of common stock by certain persons |
SC 13G |
Other |
|
|
January 30, 2017 |
mendment to a previously filed DRS |
DRS/A |
Registration Statements |
|
|
December 21, 2016 |
UPLOAD |
UPLOAD |
Other |
|
|
November 23, 2016 |
Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy |
DRS |
Registration Statements |
|
|
July 20, 2016 |
|
D |
Other |
Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.
